EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study

Takao Hirano, Akane Kumazaki, Ryuji Tomihara, Syun Ito, Ken Hoshiyama, Toshinori Murata

Scientific Reports · 2023

DOI: 10.1038/s41598-023-37726-5 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Scientific Reports, 2023. Verfasst von Takao Hirano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. takaoh@shinshu-u.ac.jp. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Diabetes Mellitus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our retrospective, single-center, observational study aimed to evaluate the initial responses to intravitreal injection of brolucizumab (IVBr) in patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). In total, 23 eyes of 20 patients with DME treated with at least one intravitreal injection of ranibizumab or aflibercept within one year and then switched to IVBr were included. Best corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume (MV) on optical coherence tomography images were evaluated just before the most recent conventional anti-VEGF (ranibizumab/aflibercept) injection therapy (V1), one month after the most recent traditional anti-VEGF therapy (V2), just before the first IVBr (V3), and one month after the first IVBr (V4). BCVA, CMT, MV, and presence of intraocular inflammation (IOI) were evaluated at each visit. Anterior chamber flare values were also examined at V3 and V4. BCVA showed significant improvement at V2 (0.30 ± 0.23) than V1 (0.39 ± 0.29) and at V4 (0.34 ± 0.26) than V3 (0.48 ± 0.34) ( P = 0.002, P < 0.001). However, no significant difference was observed between V2 and V4 ( P = 0.257). CMT was significantly thinner at V2 (346.8 ± 90.2 µm) than V1 (495.5 ± 123.8 µm), and at V4 (322.2 ± 95.7 µm) than V3 (536.5 ± 166.0 µm) ( P < 0.001, P < 0.001), but no significant difference was observed between V2 and V4 ( P = 0.140). MV was significantly smaller at V2 (11.6 ± 2.0 mm 3 ) than V1 (12.6 ± 1.9 mm 3 ) and at V4 (11.2 ± 2.0 mm 3 ) than V3 (12.6 ± 2.0 mm 3 ) ( P < 0.001, P < 0.001), and even significantly smaller at V4 than V2 ( P = 0.009). No patient had IOI. No significant changes were observed in anterior chamber flare values between V3 and V4 (25.6 ± 14.6 vs. 24.0 ± 11.5 photon count/ms; P = 0.543). Both CMT and MV significantly reduced without any adverse events one month after switching from conventional anti-VEGF to IVBr therapy for DME, including IOI. MV was significantly lower for IVBr than anti-VEGF therapy after one month of treatment. Therefore, brolucizumab may be a viable treatment option for DME patients considering switching from conventional anti-VEGF agents for various reasons, such as poor response or inability to extend dosing intervals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyDiabetes MellitusHumansRanibizumabAngiogenesis InhibitorsBevacizumabRetrospective StudiesVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsTomography, Optical CoherenceIntravitreal InjectionsTreatment OutcomeAntibodies, Monoclonal, Humanized

Substanzen

RanibizumabAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsbrolucizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. takaoh@shinshu-u.ac.jp.
  • Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
  • Department of Ophthalmology, Suwa Red Cross Hospital, Suwa, Nagano, Japan.

Zitieren

APA

Hirano, T., Kumazaki, A., Tomihara, R., Ito, S., Hoshiyama, K., & Murata, T. (2023). Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Scientific Reports. https://doi.org/10.1038/s41598-023-37726-5

Vancouver

Hirano T, Kumazaki A, Tomihara R, Ito S, Hoshiyama K, Murata T. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Scientific Reports. 2023. doi:10.1038/s41598-023-37726-5

BibTeX
@article{Hirano2023,
  author = {Hirano, Takao and Kumazaki, Akane and Tomihara, Ryuji and Ito, Syun and Hoshiyama, Ken and Murata, Toshinori},
  title = {Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study},
  journal = {Scientific Reports},
  year = {2023},
  doi = {10.1038/s41598-023-37726-5}
}
Kostenlos starten →